# NeuroTherapeutics Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurotherapeutics-pharma

- Industry: Biotechnology
- Headquarters: Chicago, US
- Total disclosed funding: $31M
- Latest round: Series B (Dec 15, 2011)
- Investors on record: 6

## About

Based in Illinois, US and founded in 2006, NeuroTherapeutics Pharma Inc. is a developer of therapeutics for treating central nervous system disorders. NeuroTherapeutics Pharma Inc, chaired by Stephen Collins as President, CEO, and Director, raised Series A funding of USD 2.5 million in 2007. The company also raised Series B funding of USD 43 million in 2010 led by Fidelity Biosciences, MPM Capital Inc, SR One Capital Management, and Pfizer Venture Investments. Existing Investors Novo Ventures and Thomas McNerney & Partners also participated in the round. In December 2011, NeuroTherapeutics Pharma, Inc. raised USD 12 million in financing. In June 2013, NeuroTherapeutics Pharma, Inc. went out of business.

NTP developed compounds that act through a unique mechanism of action to create a class of medicines used to treat neurological and neuropsychiatric conditions.NTP developed a pipeline of compounds for CNS (central nervous system) disorders. The company’s NTP compounds help patients reverse neuropathic, inflammatory, and nociceptive (acute) pain. For models of epilepsy, anxiety, and migraine, NTP compounds enable help patients to reduce seizure activity.

## Funding rounds

- Series B, Dec 15, 2011, $12M — Thomas, McNerney & Partners, Novo Holdings, F-Prime Capital, MPM BioImpact, Pfizer Venture Investments
- Series B, May 27, 2010, $19M — Thomas, McNerney & Partners, SR One, Novo Holdings, F-Prime Capital, MPM BioImpact, Pfizer Venture Investments

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Novo Holdings — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B